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Abstract
Introduction The tight junction molecule Claudin 18.2 is selectively expressed in healthy and malignant gastric epithelial 
tissue and is a promising therapy target for high Claudin 18.2 expressing adenocarcinomas of the esophagogastric junction 
and stomach (AEG/S).
Methods This study analyzed the prevalence, characteristics and prognostic impact of Claudin 18.2 expression in primary 
tumor, lymph node and distant metastasis in a large Caucasian AGE/S cohort with 414 patients.
Results Claudin 18.2 was highly expressed in 17.1% of primary tumors, 26.7% of lymph node metastasis and 16.7% of 
distant metastasis. High Claudin 18.2 expression in lymph node metastasis and primary tumors correlated significantly 
(p < 0.001). High expression of Claudin 18.2 was neither associated with histomorphogical subtype, or tumor state, nor 
with overall survival.
Conclusion In Caucasian AEG/S patients, 17.1% appeared to be eligible for an anti-Claudin 18.2 therapy. Claudin 18.2 
expression itself has no impact on prognosis and is not related to any tumor subtype.
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Introduction
In 2018, about 783,000 people died due to adenocarcinoma 
of the esophagogastric junction and stomach (AEG/S) 
worldwide [1]. Despite an increasing number of targeted-
therapy options in many tumor entities, the therapeutic 
options in AEG/S are limited to cytotoxic chemotherapy, 
anti-Her2- and anti-VEGFR2 strategies [2, 3].
Sahin et al. (2008) identified the tight junction molecule 
Claudin-18 isoform 2 as a promising target in AEG/S ther-
apy [4]. They found that the isoform Claudin 18.2 is strictly 
expressed in differentiated epithelial cells of the gastric 
mucosa and also in 75% of AEG/S.
In phase I and IIa clinical trials, the therapeutic use 
of the monoclonal anti-Claudin 18.2 antibody Clau-
diximab (IMAB362) was well tolerated and the therapy 
demonstrated a 10% response rate, a 30% disease control 
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rate in a monotherapy PHASE II study (MONO trial, 
NCT01197885), and a response rate of 39% in a combi-
nation PHASE II study with epirubicin, oxaliplatin, and 
capecitabine (EOX) (FAST trial, NCT01630083) [5, 6]. 
Due to the promising phase I/II data, several phase III 
studies are underway (NCT03528629, NCT03505320, 
NCT03653507, NCT03504397 (SPOTLIGHT)).
The characteristic of Claudin 18.2-positive AEG/S 
tumors have been recently analyzed in three retrospective 
studies. The first Japanese study detected a medium to high 
Claudin 18.2 expression in 51.5% of their patients. Clau-
din 18.2 expression was correlated with a diffuse histo-
logic subtype [7]. Another study conducted by Dottermuch 
et al. was performed in a large Caucasian gastric cancer 
cohort of 481 patients [8]. In contrast to the MONO trial 
and to the analysis of Rhode et al., they used as CLAU-
DIN 18.2 antibody the clone EPR19202. In this study, they 
could detect a significantly increased expression (> 50% 
positive tumor cells, intensity 2 +) of Claudin 18.2 in only 
two patients (0.4%). The most recent study from Caoti 
et al. using clone 34H14L15 and including a cohort of 
523 AEG/S patients detected high Claudin expression in 
29.4% of patients. Moreover, in their study Claudin 18.2. 
expression was correlated with a diffuse histologic sub-
type, corpus localization and EBV-associated subtype [9].
In summary, Claudin 18.2 is a tight junction molecule 
selectively expressed in gastric epithelial cells and seems 
to be a promising target in AEG/S. Although Claudin 18.2 
has been thoroughly characterized, solid survival data that 
are crucial for the analysis of the prognostic impact of 
Claudin 18.2 are still missing.
This study analyzes the prognostic impact of Claudin 
18.2 expression in a large retrospective AEG/S cohort 
with a long follow-up time. Furthermore, we compared 
both antibodies, clone 43-14A applied in the FAST trial 
and in the ongoing SPOTLIGHT trial as well as the clone 
EPR19202, used by Dottermusch et  al., to understand 




Clinical data from 414 patients with AEG/s of all tumor 
stages, primarily treated by surgery between 1992 and 
2004 at the Charité—Universitätsmedizin Berlin, were 
collected retrospectively. The mean follow-up was 
121.7 months (95% CI 113.9–129.5). The data includ-
ing patient characteristics and follow-up information 
were retrieved from the patient management software 
(SAP®) and the regional population-based cancer regis-
try (“Gemeinsames Krebsregister”) and are summarized 
in Table 1. This study was approved by the Institutional 
Review Board of the Charité (EA4/115/10).
Tissue samples
Out of FFPE tumor samples from 414 patients (primary 
tumors n = 392, synchronous lymph node metastasis 
n = 151 and synchronous distant metastasis n = 40), tis-
sue-micro arrays (TMA) were engineered and analyzed 
histomorphologically as described before [10]. Immuno-
histochemical analysis was performed on TMA sections 
using two different Claudin 18.2-specific monoclonal anti-
bodies: clone EPR19202 (Abcam, Cambridge, UK, dilu-
tion: 1:500) and clone 43-14A (Roche Ventana Medical 
Systems, dilution: 1:1). The immunostaining was carried 
out using the Leica Bond-Max Autostainer (Leica Biosys-
tems. IL, USA) according to the manufacturer’s protocol. 
After heat-induced epitope retrieval, the sections were 
incubated with the described antibodies. Horseradish per-
oxidase-labeled anti-rabbit-IgG using the Bond Polymer 
Detection Kit (Leica Biosystems. IL, USA) was employed 
to uncover the chromogen substrate.
Expression was evaluated by an immunoreactivity 
score (IRS): percentage of stained tumor cells (0 = 0%. 
1 = 1–25%. 2 = 26–50%. 3 = 51–75%. 4 = 76–100%) was 
multiplied with the staining intensity (score 0–3 = no 
staining to strong staining) to give the IRS score of each 
sample (score 0–12). Samples with IRS > 8 were assessed 
as Claudin 18.2-positive tumors, and samples with < / = 8 
as Claudin 18.2-negative tumors.
HER2 expression was determined by immunohisto-
chemistry using a monoclonal anti-HER2 antibody (clone 
4B5; Ventana Medical Systems). HER2 status was deter-
mined according to the consensus panel recommendation 
on HER2 testing in gastric cancer [11].
Statistics
Statistical analysis was performed using IBM SPSS Ver-
sion 24. Overall survival was defined as time from diag-
nosis to death or last follow-up and was compared using 
Kaplan–Meier method with the log-rank test for assess-
ment of statistical significance.
Associations of Claudin 18.2 expression with tumor 
size, distant and lymph node metastasis, venous and lym-
phatic infiltration, Lauren and Ming classification, grading 
and UICC classification were tested using the χ2 test.
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Table 1  Patient characteristics 
of the analyzed patient cohort 
and distribution of Claudin 
18.2-positive and -negative 
primary tumors
All Claudin 18.2 p
Total Neg Pos
n (%) n (%) N (%)
Gender
 Female 157 (41.2) 136 86.6 21 13.4 0.071
 Male 224 (58.8) 180 80.4 44 19.6
Age group
  < 65 years 215 (56.4) 179 83.3 36 16.7 0.891
  >  = 65 years 166 (43.6) 137 82.5 29 17.5
Localization
 Gastric Cancer 325 (85.3) 267 82.2 58 17.8 0.218
 AEG 56 (14.7) 49 87.5 7 12.5
Tumor stage
 T1 91 (23.9) 73 80.2 18 19.8 0.147
 T2 152 (39.9) 130 85.5 22 14.5
 T3 106 (27.8) 89 84.0 17 16.0
 T4 31 (8.1) 24 77.4 7 22.6
 Unknown 1 (0.3) 0 0.0 1 100.0
Node stage
 N0 158 (41.5) 128 81.0 30 19.0 0.400
 N + 223 (58.5) 188 84.3 35 15.7
Distant metastasis
 M0 288 (75.6) 235 81.6 53 18.4 0.472
 M1 85 (22.3) 74 87.1 11 12.9
 Unknown 8 (2.1) 7 87.5 1 12.5
Lymphatic vessel invasion
 L0 138 (36.2) 111 80.4 27 19.6 0.103
 L1 188 (49.3) 161 85.6 27 14.4
 Unknown 55 (14.4) – –
Vein invasion
 V0 214 (56.2) 179 83.6 35 16.4 0.169
 V1 105 (27.6) 88 83.8 17 16.2
 Unknown 62 (16.3) – –
Grading
 G1 8 (2.1) 7 87.5 1 12.5 0.661
 G2 105 (27.6) 84 80.0 21 20.0
 G3 265 (69.6) 223 84.2 42 15.8
 Unknown 3 (0.8)
Lauren classification
 Intestinal 160 (42.0) 131 81.9 29 18.1 0.696
 Diffuse 167 (43.8) 142 85.0 25 15.0
 Mixed 51 (13.4) 41 80.4 10 19.6
 Unknown 3 (0.8)
Ming classification
 Expansive 158 (41.5) 131 82.9 27 17.1 0.182
 Infiltrative 216 (56.7) 181 83.8 35 16.2
 Unknown 7 (1.8)
Her2Neu
 Neg 303 (79.5) 248 81.8 55 18.2 0.501
 Pos 29 (7.6) 26 89.7 3 10.3
 Unknown 49 (12.9) – – – –




The detailed clinicopathological characteristics are sum-
marized in Table 1.
Claudin 18.2 expression in primary tumors using 
clone EPR19202
Using clone EPR19202, Claudin 18.2 staining was evalu-
able in 381 of 392 primary tumors (97.2%), 146 of 151 
lymph node metastases (96.7%) and 36 of 40 distant 
metastases (90.0%). Staining with clone EPR19202 
resulted in a weak staining. No sample reached an IRS > 8. 
Eight samples (2.1%) were scored with an IRS 4–6 and 15 
(3.9%) with IRS 1–3 (see Figure S1).
Claudin 18.2 expression in primary tumors using 
clone 43‑14A
From 392 primary tumor samples, 381 samples (97.2%) 
were evaluable after staining with Clone 43-14A. High 
Claudin 18.2-positive tumor samples, defined by an 
IRS > 8, were identified in 65 cases (17.1%) (Figure 1). 
Samples were scored in 47.0% (n = 179) as IRS = 0, in 
14.2% (n = 54) as IRS 1–3, in 21.8% (n = 83) as IRS 4–8 
and in 17.1% (n = 65) IRS > 8. There was no difference in 
Claudin 18.2 expression between old and younger FFPE 
samples (× 2 p = 0.581).
The comparison of both antibodies showed that high 
scored samples in the 43-14A staining were those samples 
which also showed the highest IRS with use of EPR19202 
(see Table S1) (× 2 p < 0.0001). The correlation of Clau-
din 18.2 expression status and patient characteristics was 
negative (see Table 1). There were no differences in over-
all survival or disease-specific survival between Claudin 
18.2-positive and -negative patients (see Fig. 2).
Claudin 18.2 expression in lymph node and distant 
metastasis
From 151 lymph node samples, staining was evaluable in 
149 samples (98.7%). Claudin 18.2 expression was identi-
fied in 39 of 146 lymph node metastasis samples (26.7%). 
116 of these samples could be matched with the primary 
tumor samples from the same patient. In 78.1% (n = 68), 
Claudin 18.2-negative lymph node metastasis had cor-
responding negative primary tumor and in 70.1% (n = 23) 
Claudin 18.2-positive lymph node metastasis corresponded 
with positive primary tumors (p < 0.0001) (see Table 2).
From 40 distant metastasis samples, staining was evalu-
able in 36 samples (90.0%). Claudin 18.2 expression was 
identified in 6 of 36 distant metastasis samples (16.7%). 
Twelve of the 63 distant metastasis samples had correspond-
ing primary tumor samples from the same patient. In 68.8% 
(n = 11), Claudin 18.2-negative distant metastasis had the 
corresponding negative primary tumor and in 0% (n = 0) 
Claudin 18.2-positive distant metastasis had correspondent 
positive primary tumors (p = 0.506) (see Table 2).
Discussion
Tight junction molecule Claudin 18.2 has been found to be 
a promising target in AEG/S therapy as it is only expressed 
in healthy and some cases of malignant gastric epithelial 
tissue [4].
The present study analyzed the frequency of high Claudin 
18.2 expression, the prognostic impact and the correlation 
with histo-morphological risk groups in a large Caucasian 
AEG/S population. Using clone 43-14A for immunostain-
ing, we detected 17.1% patients with a high Claudin 18.2 
expression, which is similar to the results of the MONO trial 
(14.4%) [6]. These data are not congruent with data from a 
Japanese Gastric cancer cohort which detected in 135 of 262 
cases a strong Claudin 18.2 expression (51.5%) [7]. The dif-
ferences of expression between our Caucasian cohort and the 
Japanese cohort might be an effect of ethnical difference in 
Table 1  (continued) All Claudin 18.2 p
Total Neg Pos
n (%) n (%) N (%)
MMR
 Proficient 316 (79.5) 198 62.7 118 37.3 0.310
 Deficient 38 (7.6) 27 71.1 11 28.9
 Unknown 27 (12.9) – – – –
Significance calculated by X2 test
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Claudin 18.2 expression and will be elucidated by the data of 
the international recruiting NCT03504397 Trial (Spotlight).
The differences between our data and the data from Dot-
termusch et al. seem to be related to the use of the different 
antibodies used for IHC. When we used the same clone as 
Dottermusch et al. [8] (EPR19202), we got the same weak 
staining intensity as descripted by the authors. Table S1 
makes the differences of EPR19202 and 43-14A clear and 
shows that the sensitivity of 43-14A is higher and should be 
used for Claudin 18.2 diagnostics. The results from Claudin 
18.2 expression analysis in lymph node and distant metas-
tasis indicate that Claudin 18.2 diagnostics should be per-
formed on primary tumors and lymph node metastasis, but 
not on distant metastasis.
Fig. 1  Representative Claudin 18.2 IHC staining of TMA cores using the anti-CLDN 18.2 clone 43-14A. Examples of tumor samples with 
IRS = 0.4.6 and 12 (100 × and 400 × magnitude)
Table 2  Distribution of Claudin 18.2-negative and -positive stained 
primary tumors and their correspondent lymph node (N) and distant 
metastasis (M)
Significance calculated by X2 test
CLDN 18.2 Negative Positive p value (× 2)
N Negative 68 (78.1%) 19 (21.8%)
Positive 6 (20.7%) 23 (70.1%)  < 0.0001
M Negative 11 (68.8%) 5 (31.2%)
Positive 1 (100%) 0 (0.0%) 0.506
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Our data show that the expression of Claudin 18.2 in Cau-
casian AEG/S patients is not associated with overall survival 
and is not related to any histo-morphological subtype. In 
summary, Claudin 18.2 is not a prognostic biomarker regard-
ing the REMARK criteria [12]. Outside of a potential clau-
diximab therapy, the expression of Claudin 18.2 does not 
contain any information that is useful for disease manage-
ment. This result is consistent with the fact that Claudin 18.2 
is not part of any cancer-related pathway and the effect of 
anti-Claudin 18.2 therapy is raised by antibody-dependent 
cellular cytotoxicity [13]. Clinical trials must show whether 
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